Targeting Tumor-infiltrating Tregs for Improved Antitumor Responses

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Mar 19

PMID 38500876

Authors

Diyuan Qin

Yugu Zhang

Pei Shu

Yanna Lei

Xiaoyu Li

Yongsheng Wang

Affiliations

Soon will be listed here.

Abstract

Immunotherapies have revolutionized the landscape of cancer treatment. Regulatory T cells (Tregs), as crucial components of the tumor immune environment, has great therapeutic potential. However, nonspecific inhibition of Tregs in therapies may not lead to enhanced antitumor responses, but could also trigger autoimmune reactions in patients, resulting in intolerable treatment side effects. Hence, the precision targeting and inhibition of tumor-infiltrating Tregs is of paramount importance. In this overview, we summarize the characteristics and subpopulations of Tregs within tumor microenvironment and their inhibitory mechanisms in antitumor responses. Furthermore, we discuss the current major strategies targeting regulatory T cells, weighing their advantages and limitations, and summarize representative clinical trials targeting Tregs in cancer treatment. We believe that developing therapies that specifically target and suppress tumor-infiltrating Tregs holds great promise for advancing immune-based therapies.

Citing Articles

Promising Cellular Immunotherapy for Colorectal Cancer Using Classical Dendritic Cells and Natural Killer T Cells.

Singer M, Valerin J, Zhang Z, Zhang Z, Dayyani F, Yaghmai V Cells. 2025; 14(3).

PMID: 39936958 PMC: 11817869. DOI: 10.3390/cells14030166.

Quantitative Approach to Explore Regulatory T Cell Activity in Immuno-Oncology.

Serrano A, Zalba S, Lasarte J, Troconiz I, Riva N, Garrido M Pharmaceutics. 2024; 16(11).

PMID: 39598584 PMC: 11597491. DOI: 10.3390/pharmaceutics16111461.

Regulatory T cells in immune checkpoint blockade antitumor therapy.

Zhang A, Fan T, Liu Y, Yu G, Li C, Jiang Z Mol Cancer. 2024; 23(1):251.

PMID: 39516941 PMC: 11545879. DOI: 10.1186/s12943-024-02156-y.

Hypoxia-driven lncRNA CTD-2510F5.4: a potential player in hepatocellular carcinoma's prognostic stratification, cellular behavior, tumor microenvironment, and therapeutic response.

Abulihaiti Z, Li W, Yang L, Zhang H, Du A, Tang N Mol Biol Rep. 2024; 51(1):905.

PMID: 39133347 DOI: 10.1007/s11033-024-09826-6.

T cell receptor clonotype in tumor microenvironment contributes to intratumoral signaling network in patients with colorectal cancer.

Song I, Lee S, Jeong B, Park J, Kim H, Lee G Immunol Res. 2024; 72(5):921-937.

PMID: 39112913 DOI: 10.1007/s12026-024-09478-5.

References

Holmgaard R, Zamarin D, Li Y, Gasmi B, Munn D, Allison J . Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. Cell Rep. 2015; 13(2):412-24. PMC: 5013825. DOI: 10.1016/j.celrep.2015.08.077. View

Young A, Mittal D, Stagg J, Smyth M . Targeting cancer-derived adenosine: new therapeutic approaches. Cancer Discov. 2014; 4(8):879-88. DOI: 10.1158/2159-8290.CD-14-0341. View

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

Tanaka A, Sakaguchi S . Targeting Treg cells in cancer immunotherapy. Eur J Immunol. 2019; 49(8):1140-1146. DOI: 10.1002/eji.201847659. View

Chang C, Qiu J, OSullivan D, Buck M, Noguchi T, Curtis J . Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015; 162(6):1229-41. PMC: 4864363. DOI: 10.1016/j.cell.2015.08.016. View

Sato K, Sato N, Xu B, Nakamura Y, Nagaya T, Choyke P . Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy. Sci Transl Med. 2016; 8(352):352ra110. PMC: 7780242. DOI: 10.1126/scitranslmed.aaf6843. View

Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V . Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009; 69(5):2000-9. DOI: 10.1158/0008-5472.CAN-08-2360. View

Walker L, Sansom D . The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. 2011; 11(12):852-63. DOI: 10.1038/nri3108. View

Champiat S, Ferrara R, Massard C, Besse B, Marabelle A, Soria J . Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol. 2018; 15(12):748-762. DOI: 10.1038/s41571-018-0111-2. View

10.

Kondo Y, Ohno T, Nishii N, Harada K, Yagita H, Azuma M . Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma. Oral Oncol. 2016; 57:54-60. DOI: 10.1016/j.oraloncology.2016.04.005. View

11.

Filin I, Kitaeva K, Rutland C, Rizvanov A, Solovyeva V . Recent Advances in Experimental Dendritic Cell Vaccines for Cancer. Front Oncol. 2021; 11:730824. PMC: 8495208. DOI: 10.3389/fonc.2021.730824. View

12.

Khattri R, Cox T, Yasayko S, Ramsdell F . An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol. 2003; 4(4):337-42. DOI: 10.1038/ni909. View

13.

Linsley P, Greene J, Brady W, Bajorath J, Ledbetter J, Peach R . Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity. 1994; 1(9):793-801. DOI: 10.1016/s1074-7613(94)80021-9. View

14.

Watson M, Vignali P, Mullett S, Overacre-Delgoffe A, Peralta R, Grebinoski S . Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature. 2021; 591(7851):645-651. PMC: 7990682. DOI: 10.1038/s41586-020-03045-2. View

15.

de Oliveira C, Gasparoto T, Pinheiro C, Amor N, Nogueira M, Kaneno R . CCR5-Dependent Homing of T Regulatory Cells to the Tumor Microenvironment Contributes to Skin Squamous Cell Carcinoma Development. Mol Cancer Ther. 2017; 16(12):2871-2880. DOI: 10.1158/1535-7163.MCT-17-0341. View

16.

Hindley J, Ferreira C, Jones E, Lauder S, Ladell K, Wynn K . Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors. Cancer Res. 2010; 71(3):736-46. PMC: 3128990. DOI: 10.1158/0008-5472.CAN-10-1797. View

17.

Hori S, Nomura T, Sakaguchi S . Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003; 299(5609):1057-61. DOI: 10.1126/science.1079490. View

18.

Flavell R, Sanjabi S, Wrzesinski S, Licona-Limon P . The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol. 2010; 10(8):554-67. PMC: 3885992. DOI: 10.1038/nri2808. View

19.

van Hooren L, Sandin L, Moskalev I, Ellmark P, Dimberg A, Black P . Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer. Eur J Immunol. 2016; 47(2):385-393. DOI: 10.1002/eji.201646583. View

20.

Wei S, Kryczek I, Zou W . Regulatory T-cell compartmentalization and trafficking. Blood. 2006; 108(2):426-31. PMC: 1895488. DOI: 10.1182/blood-2006-01-0177. View